AUT LibraryAUT
View Item 
  •   Open Research
  • AUT Faculties
  • Faculty of Health and Environmental Sciences
  • School of Science
  • View Item
  •   Open Research
  • AUT Faculties
  • Faculty of Health and Environmental Sciences
  • School of Science
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

SHON Expression Predicts Response and Relapse Risk of Breast Cancer Patients After Anthracycline-based Combination Chemotherapy or Tamoxifen Treatment

Abdel-Fatah, TMA; Broom, RJ; Lu, J; Moseley, PM; Huang, B; Li, L; Liu, S; Chen, L; Ma, RZ; Cao, W; Wang, X; Li, Y; Perry, JK; Aleskandarany, M; Nolan, CC; Rakha, EA; Lobie, PE; Chan, SYT; Ellis, IO; Hwang, LA; Lane, DP; Green, AR; Liu, DX
Thumbnail
View/Open
Journal article (2.022Mb)
Permanent link
http://hdl.handle.net/10292/15328
Metadata
Show full metadata
Abstract
Background: SHON nuclear expression (SHON-Nuc + ) was previously reported to predict clinical outcomes to tamoxifen therapy in ERα + breast cancer (BC). Herein we determined if SHON expression detected by specific monoclonal antibodies could provide a more accurate prediction and serve as a biomarker for anthracycline-based combination chemotherapy (ACT). Methods: SHON expression was determined by immunohistochemistry in the Nottingham early-stage-BC cohort (n = 1,650) who, if eligible, received adjuvant tamoxifen; the Nottingham ERα − early-stage-BC (n = 697) patients who received adjuvant ACT; and the Nottingham locally advanced-BC cohort who received pre-operative ACT with/without taxanes (Neo-ACT, n = 120) and if eligible, 5-year adjuvant tamoxifen treatment. Prognostic significance of SHON and its relationship with the clinical outcome of treatments were analysed. Results: As previously reported, SHON-Nuc + in high risk/ERα + patients was significantly associated with a 48% death risk reduction after exclusive adjuvant tamoxifen treatment compared with SHON-Nuc − [HR (95% CI) = 0.52 (0.34–0.78), p = 0.002]. Meanwhile, in ERα − patients treated with adjuvant ACT, SHON cytoplasmic expression (SHON-Cyto + ) was significantly associated with a 50% death risk reduction compared with SHON-Cyto − [HR (95% CI) = 0.50 (0.34–0.73), p = 0.0003]. Moreover, in patients received Neo-ACT, SHON-Nuc − or SHON-Cyto + was associated with an increased pathological complete response (pCR) compared with SHON-Nuc + [21 vs 4%; OR (95% CI) = 5.88 (1.28–27.03), p = 0.012], or SHON-Cyto − [20.5 vs. 4.5%; OR (95% CI) = 5.43 (1.18–25.03), p = 0.017], respectively. After receiving Neo-ACT, patients with SHON-Nuc + had a significantly lower distant relapse risk compared to those with SHON-Nuc − [HR (95% CI) = 0.41 (0.19–0.87), p = 0.038], whereas SHON-Cyto + patients had a significantly higher distant relapse risk compared to SHON-Cyto − patients [HR (95% CI) = 4.63 (1.05–20.39), p = 0.043]. Furthermore, multivariate Cox regression analyses revealed that SHON-Cyto + was independently associated with a higher risk of distant relapse after Neo-ACT and 5-year tamoxifen treatment [HR (95% CI) = 5.08 (1.13–44.52), p = 0.037]. The interaction term between ERα status and SHON-Nuc + (p = 0.005), and between SHON-Nuc + and tamoxifen therapy (p = 0.007), were both statistically significant. Conclusion: SHON-Nuce + in tumours predicts response to tamoxifen in ERα + BC while SHON-Cyto + predicts response to ACT.
Keywords
Molecular medicine; Predictive markers; Prognostic markers
Date
2019
Source
British Journal of Cancer 120, 728–745 (2019). https://doi.org/10.1038/s41416-019-0405-x
Item Type
Journal Article
Publisher
Springer Nature
DOI
10.1038/s41416-019-0405-x
Publisher's Version
https://www.nature.com/articles/s41416-019-0405-x
Rights Statement
© 2019, Cancer Research UK. This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0)

Contact Us
  • Admin

Hosted by Tuwhera, an initiative of the Auckland University of Technology Library

 

 

Browse

Open ResearchTitlesAuthorsDateSchool of ScienceTitlesAuthorsDate

Alternative metrics

 

Statistics

For this itemFor all Open Research

Share

 
Follow @AUT_SC

Contact Us
  • Admin

Hosted by Tuwhera, an initiative of the Auckland University of Technology Library